Understanding Asymptomatic Carotid Stenosis
Asymptomatic carotid stenosis refers to the narrowing of the carotid arteries—the major blood vessels supplying oxygen-rich blood to the brain—without any recent symptoms such as transient ischemic attacks (TIAs) or strokes attributable to that artery. Carotid artery stenosis (CAS), often caused by atherosclerotic plaque buildup, affects approximately 1-2% of the general population over age 70, with higher prevalence in those with cardiovascular risk factors like hypertension, diabetes, hyperlipidemia, and smoking. In Europe, where aging populations are prevalent, this condition poses a significant public health challenge, contributing to up to 20% of ischemic strokes despite patients remaining symptom-free.
The plaque can embolize or cause hypoperfusion, leading to ipsilateral stroke risks estimated at 0.5-1.5% per year under modern medical therapy. Diagnosis typically involves duplex ultrasonography, CT angiography (CTA), or magnetic resonance angiography (MRA), confirming ≥70% stenosis as a high-risk threshold. European clinicians, guided by the European Society for Vascular Surgery (ESVS) 2023 guidelines, have historically favored selective revascularization for low-risk patients, emphasizing intensive medical optimization first.
This conservative approach stems from trials like ACST-1 and SPACE-2, which questioned routine intervention amid plummeting event rates with contemporary pharmacotherapy. However, the recent CREST-2 study has reignited debate by providing fresh randomized evidence on revascularization's role.
Evolution of Management Strategies Over Decades
Historical shifts in asymptomatic CAS management mirror advances in both procedural techniques and pharmacotherapy. Early trials like the Asymptomatic Carotid Atherosclerosis Study (ACAS, 1995) and Asymptomatic Carotid Surgery Trial (ACST-1, 2004) demonstrated carotid endarterectomy (CEA)—surgical plaque removal—reduced 5-year stroke risk from 11% to 5.1% (ACAS) versus medical therapy of the era (aspirin alone). Carotid artery stenting (CAS), a less invasive endovascular alternative, emerged in the 2000s, with CREST (2010) equating CEA and CAS efficacy in symptomatic patients.
By the 2010s, high-intensity statins (e.g., atorvastatin 40-80mg), dual antiplatelet therapy (DAPT: aspirin + clopidogrel), strict blood pressure control (<140/90 mmHg), and lifestyle interventions halved annual stroke risks to <1%, prompting trials like SPACE-2 (2019) and interim ECST-2 data showing no revascularization benefit. ESVS guidelines (2023) recommend CEA for <6% perioperative risk patients with >60-99% stenosis (Class IIa), but only after optimizing medical therapy. Post-CREST-2, European experts note the trial's intensive medical arm achieved even lower event rates, underscoring therapy's potency while highlighting CAS's potential edge.
Design and Methodology of the Landmark CREST-2 Trials
The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial-2 (CREST-2), published in the New England Journal of Medicine on November 21, 2025, comprised two parallel, multicenter, observer-blinded randomized trials across 155 sites in the US, Canada, and Europe. Eligibility required age ≥35, ≥70% asymptomatic stenosis (confirmed by ultrasound/CTA/MRA), no ipsilateral symptoms in 180 days, and life expectancy ≥5 years.
Randomization: 1,245 to stenting + medical vs. medical alone; 1,240 to CEA + medical vs. medical alone. Operators were credentialed (≥50 CEAs or ≥100 transfemoral CAS cases). Primary outcome: composite of any stroke/death (days 0-44) or ipsilateral ischemic stroke (up to 4 years). Intensive medical management—uniform across arms—included DAPT (90 days then aspirin 81-325mg), high-dose statin (LDL <70 mg/dL, PCSK9 inhibitors if needed), BP <140/90 mmHg (target <130 initially), HbA1c <7%, smoking cessation, diet/exercise coaching, with free meds/telehealth. Follow-up: annual visits/imaging. Funded by NIH/NINDS.
The design addressed prior trial limitations by powering for modern low event rates (80% power for 1.3% absolute reduction), excluding high-risk anatomy, and mandating optimal medical therapy—a protocol achieving >70% target adherence.
Breakthrough Results from the Carotid Stenting Arm
In the CAS arm, 4-year primary outcome incidence was 2.8% (95% CI 1.5-4.3%) with stenting + medical vs. 6.0% (95% CI 3.8-8.3%) with medical alone (absolute difference 3.2%, P=0.02; HR 0.46). Number needed to treat (NNT): 31 to prevent one event. Peri-procedural (0-44 days): 1.3% events (7 strokes, 1 death) in stenting vs. 0% medical; post-44 days, annual ipsilateral stroke 0.4% vs. 1.7% (RR 4.07). Disabling strokes rare (<0.5% annual). Benefits consistent across subgroups (age, sex, comorbidities).
Secondary revascularization lower (4.7% vs. 18.8%), all-cause mortality similar (7.1% vs. 11.0%). This marks the first RCT showing CAS superiority over intensive medical therapy in asymptomatic CAS, contrasting SPACE-2's null findings.NEJM CREST-2 Publication
Findings from the Endarterectomy Arm: No Significant Edge
The CEA arm showed 3.7% (95% CI 2.1-5.5%) primary events with CEA + medical vs. 5.3% (95% CI 3.3-7.4%) medical alone (absolute difference 1.6%, P=0.24; not significant). Peri-procedural strokes: 0.7% CEA vs. 0.2% medical; post-peri annual ipsilateral stroke 0.5% vs. 1.3% (RR 2.38). NNT not met due to lack of power post-hoc. Secondary revasc lower (7.1% vs. 21.0%), mortality 8.8% vs. 9.6%.
CEA's numerical benefit aligns with historical data but underscores medical therapy's efficacy in erasing statistical superiority under rigorous protocols.
| Arm | Medical Alone (4-yr %) | Revasc + Medical (4-yr %) | P-value |
|---|---|---|---|
| CAS | 6.0 | 2.8 | 0.02 |
| CEA | 5.3 | 3.7 | 0.24 |
Unpacking the Intensive Medical Management Protocol
CREST-2's protocol exemplifies contemporary best practice: DAPT (aspirin 81-325mg + clopidogrel 75mg x90 days), high-intensity statin/PCSK9i (LDL<70mg/dL), antihypertensives (systolic <140mmHg), glycemic control (HbA1c<7%), >150min/week exercise, Mediterranean diet, smoking cessation with counseling/free meds. Adherence: 71% LDL target, 73% BP by year 1. This halved expected event rates vs. historical controls, validating Europe's shift to medical-first strategies.
- Step 1: Risk assessment and patient education.
- Step 2: Pharmacologic titration with telemonitoring.
- Step 3: Lifestyle coaching quarterly.
- Step 4: Annual duplex surveillance.
Real-world replication challenges include adherence gaps, but CREST-2 proves feasibility.CREST-2 Trial Site
Balancing Peri-Procedural Risks with Long-Term Gains
Peri-procedural morbidity (1-1.5%) offset by post-procedural reductions (0.4-0.5% annual vs. 1.3-1.7%), yielding net benefit for CAS. Nondisabling strokes predominated; disabling <0.2%/year. SVS notes higher TF-CAS risks vs. TCAR/CEA in registries (VQI), urging operator expertise and anatomy selection (e.g., avoid type III arch). Cognitive substudy: no revascularization benefit.
For low-surgical-risk patients, CAS offers durable protection; CEA suits calcified plaques.
Reshaping European Practice: ESVS and ESC Perspectives
ESVS 2023 (pre-CREST-2) recommended CEA (Class IIa) for <3% risk patients post-medical optimization. ESC Stroke Council hails CREST-2 as paradigm-shifting, first RCT backing CAS over medical, challenging SPACE-2/ECST-2 nulls. No immediate guideline updates (as of March 2026), but expect revisions favoring selective CAS in high-volume centers. European registries (e.g., VASCUNET) report 1-2% annual medical event rates; CREST-2's 1.5% reinforces but tips toward intervention for ≥70% stenosis."The CREST-2 study challenges prior paradigms... reinforcing [CAS] as a treatment option."
Multidisciplinary teams (vascular surgeons, neurologists, interventionalists) key; shared decision-making emphasized amid aging demographics.Explore vascular research jobs in Europe
Expert Reactions and Ongoing Debates
SVIN's Thanh Nguyen: "Paradigm shift" for CAS. SVS commentary cautions: optimize medical first, prefer CEA/TCAR (lower MI/cranial nerve risks), TCAR untested. Tudor Jovin: Offer revascularization post-medical trial. Martin Brown (UK): Impressive CAS data but chance-sensitive; routine CEA obsolete. Debates: generalizability (elite operators), TCAR role, plaque imaging for selection (e.g., progression on duplex).
Future Outlook: Research Frontiers and Clinical Trials
CREST-2 spurs plaque vulnerability biomarkers (e.g., echolucency, intraplaque hemorrhage via MRI), AI risk prediction, TCAR trials (CREST-3?). European initiatives: ECST-2 full results, ESVS updates. Long-term >10-year data pending. For academics, opportunities in vascular imaging, stroke prevention cohorts abound.Higher ed research positions
Actionable: Audit local medical adherence; refer select ≥70% stenosis to expert centers for CAS consideration.
Photo by Brett Jordan on Unsplash
Career Insights for Vascular Researchers in Europe
Amid CREST-2's impact, Europe's universities seek experts in endovascular trials, neuroimaging. Institutions like Oxford, Karolinska drive ESVS-aligned research. Explore faculty roles in stroke prevention; rate professors via Rate My Professor. Career advice at Higher Ed Career Advice.
